Across TCGA pan-cancer cohorts, ITSN2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ITSN2 data layer compared with 20 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ITSN2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ITSN2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where ITSN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.870	0.575	.003	8	view →
LUAD	DFS	Tertile	All	0.927	0.440	.004	6	view →
CCRCC	OS	Quartile	II,III,IV	0.981	0.067	.036	6	view →
PDAC	DFS	Quartile	All	0.538	0.323	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ITSN2 tumor-vs-normal RNA expression · all ITSN2 data types